148235-99-8 Usage
Description
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-10-(4-methyl-1,4-diazepan-1-yl)-1,6,15-trioxo-1,2-dihydro-6H,13H-2,7-(epoxypentadeca[1,11,13]trienoazeno)[1]benzofuro[4,5-a]phenoxazin-25-yl is a complex organic compound with a benzofurophenoxazin structure. It features multiple hydroxy, methoxy, and methyl groups, as well as a 1,4-diazepan-1-yl substituent and an epoxide moiety. (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-10-(4-methyl-1,4-diazepan-1-yl)-1,6,15-trioxo-1,2-dihydro-6H,13H-2,7-(epoxypentadeca[1,11,13]trienoazeno)[1]benzofuro[4,5-a]phenoxazin-25-yl's intricate structure suggests it may have a highly specific function or biological activity.
Uses
Used in Pharmaceutical Industry:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-10-(4-methyl-1,4-diazepan-1-yl)-1,6,15-trioxo-1,2-dihydro-6H,13H-2,7-(epoxypentadeca[1,11,13]trienoazeno)[1]benzofuro[4,5-a]phenoxazin-25-yl is used as a pharmaceutical agent for its potential therapeutic effects. (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-10-(4-methyl-1,4-diazepan-1-yl)-1,6,15-trioxo-1,2-dihydro-6H,13H-2,7-(epoxypentadeca[1,11,13]trienoazeno)[1]benzofuro[4,5-a]phenoxazin-25-yl's unique structure may allow it to target specific biological pathways or receptors, making it a promising candidate for the development of new drugs.
Used in Chemical Research:
In the field of chemical research, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-10-(4-methyl-1,4-diazepan-1-yl)-1,6,15-trioxo-1,2-dihydro-6H,13H-2,7-(epoxypentadeca[1,11,13]trienoazeno)[1]benzofuro[4,5-a]phenoxazin-25-yl serves as a subject of study for understanding the synthesis, properties, and potential applications of complex organic molecules. Its unique structure and functional groups may provide insights into new chemical reactions or mechanisms.
Used in Material Science:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-10-(4-methyl-1,4-diazepan-1-yl)-1,6,15-trioxo-1,2-dihydro-6H,13H-2,7-(epoxypentadeca[1,11,13]trienoazeno)[1]benzofuro[4,5-a]phenoxazin-25-yl may be utilized in material science for the development of new materials with specific properties. Its complex structure and functional groups could contribute to the creation of materials with unique characteristics, such as improved stability, reactivity, or selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 148235-99-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,2,3 and 5 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 148235-99:
(8*1)+(7*4)+(6*8)+(5*2)+(4*3)+(3*5)+(2*9)+(1*9)=148
148 % 10 = 8
So 148235-99-8 is a valid CAS Registry Number.
148235-99-8Relevant articles and documents
Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives
Yamane,Hashizume,Yamashita,Konishi,Hosoe,Hidaka,Watanabe,Kawaharada,Yamamoto,Kuze
, p. 148 - 155 (1993)
As a part of our studies on the syntheses of benzoxazinorifamycin derivatives, 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives were synthesized, and tested for their antimicrobial activities. The antimicrobial activities of these compounds against gram-positive and gram-negative bacteria were almost identical to those of rifampicin (RFP) and rifabutain (RFB), however, antimicrobial activities against Mycobacterium tuberculosis were superior to RFP, while being similar to RFB. 3'-Hydroxy-5'-(4-alkyl-1-piperazinyl)benzoxazinorifamycin derivatives also had in vitro potent activities against Mycobacterium avium complex (MAC). Their minimal inhibitory concentration values against MAC were 2-256 times greater than RFP and RFB. Their in vivo efficacies against M. tuberculosis and MAC, after oral administration to mice, were superior to RFP and REB, except for RFB against M. tuberculosis activity in vivo. Although they were absorbed from the gastrointestinal tract, their plasma levels were lower than that of RFP. Among these 5'-(4-alkyl-1-piperazinyl) derivatives, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin, compound 19 (KRM-1648), was selected as the most promising and its preliminary pharmacokinetic characteristics in mice were investigated. Compound 19 was distributed much more in tissues, especially in spleen and lung, than in plasma and had a long elimination time from tissues.
